Heron Therapeutics, Inc. (HRTX)
USD 2.08
(-3.04%)
USD 2.08
(-3.04%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 150.95 Million USD | 6.22% |
| 2022 | 142.11 Million USD | 106.1% |
| 2021 | 68.95 Million USD | 185.63% |
| 2020 | -80.52 Million USD | -54.54% |
| 2019 | -52.1 Million USD | -91.13% |
| 2018 | -27.26 Million USD | 76.48% |
| 2017 | -115.89 Million USD | -393.44% |
| 2016 | 39.49 Million USD | 154.14% |
| 2015 | -72.95 Million USD | -2.65% |
| 2014 | -71.07 Million USD | 0.26% |
| 2013 | -71.26 Million USD | -34.42% |
| 2012 | -53.01 Million USD | -196.65% |
| 2011 | -17.87 Million USD | -747.37% |
| 2010 | -2.1 Million USD | 72.22% |
| 2009 | -7.59 Million USD | 23.82% |
| 2008 | -9.96 Million USD | 70.26% |
| 2007 | -33.51 Million USD | -1336.35% |
| 2006 | -2.33 Million USD | -195.32% |
| 2005 | -790 Thousand USD | 74.6% |
| 2004 | -3.11 Million USD | -3106.19% |
| 2003 | -97 Thousand USD | 97.04% |
| 2002 | -3.28 Million USD | 9.29% |
| 2001 | -3.61 Million USD | 44.28% |
| 2000 | -6.49 Million USD | -1523.33% |
| 1999 | -400 Thousand USD | 60.0% |
| 1998 | -1 Million USD | 67.74% |
| 1997 | -3.1 Million USD | -410.0% |
| 1996 | 1 Million USD | -52.38% |
| 1995 | 2.1 Million USD | 320.0% |
| 1994 | 500 Thousand USD | -73.68% |
| 1993 | 1.9 Million USD | 46.15% |
| 1992 | 1.3 Million USD | -45.83% |
| 1991 | 2.4 Million USD | 84.62% |
| 1990 | 1.3 Million USD | 225.0% |
| 1989 | 400 Thousand USD | 104.76% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 158.72 Million USD | 5.15% |
| 2024 Q2 | 160.32 Million USD | 1.01% |
| 2023 Q3 | 145.13 Million USD | 1.74% |
| 2023 Q1 | 129.83 Million USD | -8.64% |
| 2023 Q2 | 142.66 Million USD | 9.88% |
| 2023 FY | 150.95 Million USD | 6.22% |
| 2023 Q4 | 150.95 Million USD | 4.0% |
| 2022 Q3 | 107.56 Million USD | -2.12% |
| 2022 Q4 | 142.11 Million USD | 32.12% |
| 2022 Q2 | 109.9 Million USD | 7.65% |
| 2022 FY | 142.11 Million USD | 106.1% |
| 2022 Q1 | 102.09 Million USD | 48.06% |
| 2021 FY | 68.95 Million USD | 185.63% |
| 2021 Q3 | 4.93 Million USD | 118.95% |
| 2021 Q2 | -26.01 Million USD | 26.33% |
| 2021 Q1 | -35.31 Million USD | 56.15% |
| 2021 Q4 | 68.95 Million USD | 1298.66% |
| 2020 Q1 | -77.88 Million USD | -49.48% |
| 2020 Q3 | -70.29 Million USD | -26.39% |
| 2020 Q4 | -80.52 Million USD | -14.56% |
| 2020 FY | -80.52 Million USD | -54.54% |
| 2020 Q2 | -55.61 Million USD | 28.59% |
| 2019 Q4 | -52.1 Million USD | -23.33% |
| 2019 FY | -52.1 Million USD | -91.13% |
| 2019 Q3 | -42.25 Million USD | -20.77% |
| 2019 Q2 | -34.98 Million USD | -616.15% |
| 2019 Q1 | -4.88 Million USD | 82.08% |
| 2018 Q2 | -229.82 Million USD | -1199.82% |
| 2018 FY | -27.26 Million USD | 76.48% |
| 2018 Q4 | -27.26 Million USD | 45.03% |
| 2018 Q3 | -49.59 Million USD | 78.42% |
| 2018 Q1 | -17.68 Million USD | 84.74% |
| 2017 Q4 | -115.89 Million USD | -212.88% |
| 2017 FY | -115.89 Million USD | -393.44% |
| 2017 Q1 | -30.41 Million USD | -177.01% |
| 2017 Q2 | -1.99 Million USD | 93.45% |
| 2017 Q3 | -37.04 Million USD | -1759.59% |
| 2016 Q3 | 7.09 Million USD | 111.94% |
| 2016 Q2 | -59.38 Million USD | 9.51% |
| 2016 FY | 39.49 Million USD | 154.14% |
| 2016 Q1 | -65.62 Million USD | 10.05% |
| 2016 Q4 | 39.49 Million USD | 456.92% |
| 2015 Q2 | -169.62 Million USD | -215.24% |
| 2015 Q1 | -53.8 Million USD | 24.3% |
| 2015 Q3 | -150.92 Million USD | 11.02% |
| 2015 Q4 | -72.95 Million USD | 51.66% |
| 2015 FY | -72.95 Million USD | -2.65% |
| 2014 FY | -71.07 Million USD | 0.26% |
| 2014 Q1 | -56.31 Million USD | 20.98% |
| 2014 Q4 | -71.07 Million USD | 16.15% |
| 2014 Q3 | -84.76 Million USD | 18.27% |
| 2014 Q2 | -103.7 Million USD | -84.17% |
| 2013 Q2 | -34.09 Million USD | 24.4% |
| 2013 Q3 | -21.7 Million USD | 36.33% |
| 2013 Q4 | -71.26 Million USD | -228.26% |
| 2013 FY | -71.26 Million USD | -34.42% |
| 2013 Q1 | -45.1 Million USD | 14.93% |
| 2012 FY | -53.01 Million USD | -196.65% |
| 2012 Q1 | -13.34 Million USD | 25.33% |
| 2012 Q3 | -59.64 Million USD | -388.8% |
| 2012 Q2 | -12.2 Million USD | 8.55% |
| 2012 Q4 | -53.01 Million USD | 11.12% |
| 2011 Q4 | -17.87 Million USD | 14.72% |
| 2011 FY | -17.87 Million USD | -747.37% |
| 2011 Q3 | -20.95 Million USD | 1.65% |
| 2011 Q2 | -21.3 Million USD | -1863.69% |
| 2011 Q1 | -1.08 Million USD | 48.55% |
| 2010 Q2 | -5.73 Million USD | 24.15% |
| 2010 FY | -2.1 Million USD | 72.22% |
| 2010 Q1 | -7.56 Million USD | 0.41% |
| 2010 Q3 | -3.01 Million USD | 47.44% |
| 2010 Q4 | -2.1 Million USD | 30.05% |
| 2009 Q3 | -1.56 Million USD | 56.54% |
| 2009 Q4 | -7.59 Million USD | -383.94% |
| 2009 FY | -7.59 Million USD | 23.82% |
| 2009 Q2 | -3.61 Million USD | 49.23% |
| 2009 Q1 | -7.11 Million USD | 28.66% |
| 2008 Q3 | -15.68 Million USD | 22.97% |
| 2008 Q4 | -9.96 Million USD | 36.43% |
| 2008 Q2 | -20.35 Million USD | 23.19% |
| 2008 Q1 | -26.5 Million USD | 20.91% |
| 2008 FY | -9.96 Million USD | 70.26% |
| 2007 FY | -33.51 Million USD | -1336.35% |
| 2007 Q4 | -33.51 Million USD | 11.52% |
| 2007 Q2 | -40.71 Million USD | -3950.75% |
| 2007 Q1 | -1 Million USD | 56.92% |
| 2007 Q3 | -37.87 Million USD | 6.97% |
| 2006 Q2 | -5.94 Million USD | 45.82% |
| 2006 FY | -2.33 Million USD | -195.32% |
| 2006 Q4 | -2.33 Million USD | 38.1% |
| 2006 Q3 | -3.76 Million USD | 36.58% |
| 2006 Q1 | -10.97 Million USD | -1288.61% |
| 2005 Q1 | -354 Thousand USD | 88.62% |
| 2005 FY | -790 Thousand USD | 74.6% |
| 2005 Q4 | -790 Thousand USD | 65.37% |
| 2005 Q3 | -2.28 Million USD | -15.67% |
| 2005 Q2 | -1.97 Million USD | -457.06% |
| 2004 FY | -3.11 Million USD | -3106.19% |
| 2004 Q1 | -2.4 Million USD | -2374.23% |
| 2004 Q2 | -5.81 Million USD | -142.21% |
| 2004 Q3 | -673 Thousand USD | 88.42% |
| 2004 Q4 | -3.11 Million USD | -362.11% |
| 2003 Q3 | -1.47 Million USD | -18.31% |
| 2003 FY | -97 Thousand USD | 97.04% |
| 2003 Q1 | -3.63 Million USD | -10.66% |
| 2003 Q2 | -1.24 Million USD | 65.72% |
| 2003 Q4 | -97 Thousand USD | 93.41% |
| 2002 Q4 | -3.28 Million USD | 49.94% |
| 2002 FY | -3.28 Million USD | 9.29% |
| 2002 Q1 | -4.8 Million USD | -32.73% |
| 2002 Q3 | -6.55 Million USD | -255.53% |
| 2002 Q2 | -1.84 Million USD | 61.6% |
| 2001 Q1 | -4.79 Million USD | 26.12% |
| 2001 Q4 | -3.61 Million USD | -37.7% |
| 2001 Q2 | -4.15 Million USD | 13.37% |
| 2001 FY | -3.61 Million USD | 44.28% |
| 2001 Q3 | -2.62 Million USD | 36.78% |
| 2000 Q3 | -9.9 Million USD | -5075.9% |
| 2000 Q4 | -6.49 Million USD | 34.44% |
| 2000 Q2 | 199.03 Thousand USD | 144.2% |
| 2000 Q1 | -450.3 Thousand USD | -12.58% |
| 2000 FY | -6.49 Million USD | -1523.33% |
| 1999 Q1 | -1.1 Million USD | -10.0% |
| 1999 Q2 | 300 Thousand USD | 127.27% |
| 1999 Q3 | 400 Thousand USD | 33.33% |
| 1999 Q4 | -400 Thousand USD | -200.0% |
| 1999 FY | -400 Thousand USD | 60.0% |
| 1998 Q4 | -1 Million USD | -433.33% |
| 1998 Q1 | -1.4 Million USD | 54.84% |
| 1998 FY | -1 Million USD | 67.74% |
| 1998 Q2 | -900 Thousand USD | 35.71% |
| 1998 Q3 | 300 Thousand USD | 133.33% |
| 1997 Q3 | -2.3 Million USD | -155.56% |
| 1997 Q1 | 1.4 Million USD | 40.0% |
| 1997 FY | -3.1 Million USD | -410.0% |
| 1997 Q2 | -900 Thousand USD | -164.29% |
| 1997 Q4 | -3.1 Million USD | -34.78% |
| 1996 FY | 1 Million USD | -52.38% |
| 1996 Q4 | 1 Million USD | -37.5% |
| 1996 Q1 | 2.2 Million USD | 4.76% |
| 1996 Q3 | 1.6 Million USD | 128.57% |
| 1996 Q2 | 700 Thousand USD | -68.18% |
| 1995 Q3 | - USD | -100.0% |
| 1995 Q4 | 2.1 Million USD | 0.0% |
| 1995 FY | 2.1 Million USD | 320.0% |
| 1995 Q1 | -1.1 Million USD | -320.0% |
| 1995 Q2 | 700 Thousand USD | 163.64% |
| 1994 Q2 | -3.9 Million USD | -587.5% |
| 1994 Q1 | 800 Thousand USD | -57.89% |
| 1994 Q4 | 500 Thousand USD | 119.23% |
| 1994 FY | 500 Thousand USD | -73.68% |
| 1994 Q3 | -2.6 Million USD | 33.33% |
| 1993 Q1 | 1.8 Million USD | 38.46% |
| 1993 FY | 1.9 Million USD | 46.15% |
| 1993 Q2 | 3.5 Million USD | 94.44% |
| 1993 Q3 | 2.7 Million USD | -22.86% |
| 1993 Q4 | 1.9 Million USD | -29.63% |
| 1992 Q4 | 1.3 Million USD | 143.33% |
| 1992 Q2 | -400 Thousand USD | 50.0% |
| 1992 Q1 | -800 Thousand USD | -133.33% |
| 1992 FY | 1.3 Million USD | -45.83% |
| 1992 Q3 | -3 Million USD | -650.0% |
| 1991 Q2 | 600 Thousand USD | 0.0% |
| 1991 FY | 2.4 Million USD | 84.62% |
| 1991 Q3 | 1.6 Million USD | 166.67% |
| 1991 Q4 | 2.4 Million USD | 50.0% |
| 1991 Q1 | 600 Thousand USD | -53.85% |
| 1990 Q2 | -300 Thousand USD | -200.0% |
| 1990 Q4 | 1.3 Million USD | 218.18% |
| 1990 Q3 | -1.1 Million USD | -266.67% |
| 1990 FY | 1.3 Million USD | 225.0% |
| 1990 Q1 | -100 Thousand USD | -125.0% |
| 1989 FY | 400 Thousand USD | 104.76% |
| 1989 Q4 | 400 Thousand USD | 107.02% |
| 1989 Q2 | -6.5 Million USD | 0.0% |
| 1989 Q3 | -5.7 Million USD | 12.31% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 369.844% |
| Alkermes plc | -166.73 Million USD | 190.531% |
| Agenus Inc. | 274.13 Million USD | 44.936% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 91.927% |
| Aptorum Group Limited | 1.35 Million USD | -11023.499% |
| Ardelyx, Inc. | 34.51 Million USD | -337.387% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -3426.893% |
| Bicycle Therapeutics plc | -481.46 Million USD | 131.352% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | -317.418% |
| ChromaDex Corporation | -24.04 Million USD | 727.707% |
| Chimerix, Inc. | -25.51 Million USD | 691.57% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -2066.323% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 737.543% |
| CRISPR Therapeutics AG | -150.84 Million USD | 200.07% |
| Precision BioSciences, Inc. | -85.41 Million USD | 276.737% |
| Dyadic International, Inc. | -6.37 Million USD | 2466.708% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 1047.411% |
| Fortress Biotech, Inc. | 7.66 Million USD | -1869.354% |
| Lantern Pharma Inc. | -21.7 Million USD | 795.522% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 236.562% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 1866.919% |
| Incyte Corporation | -3.17 Billion USD | 104.754% |
| IO Biotech, Inc. | -140.69 Million USD | 207.286% |
| Jaguar Health, Inc. | 29.39 Million USD | -413.596% |
| Novavax, Inc. | -298.29 Million USD | 150.605% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -2728.387% |
| Opthea Limited | 28.15 Million USD | -436.096% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 999.107% |
| ContextLogic Inc. | -232 Million USD | 165.065% |
| MiMedx Group, Inc. | -33.9 Million USD | 545.27% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -1380.638% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 6614.857% |
| NextCure, Inc. | -6.47 Million USD | 2430.57% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 398.907% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 2466.374% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -1141.04% |
| Vaxcyte, Inc. | -368.22 Million USD | 140.994% |
| PDS Biotechnology Corporation | -32.7 Million USD | 561.498% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -773.66% |
| Pharming Group N.V. | 109.8 Million USD | -37.473% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 967.734% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 186.144% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 915.077% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 915.077% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 2226.07% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 2675.956% |
| Acelyrin, Inc. | -216.9 Million USD | 169.594% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 2790.621% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 8855.858% |
| Summit Therapeutics Inc. | 34.67 Million USD | -335.343% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 2318.889% |
| Senti Biosciences, Inc. | 1.74 Million USD | -8575.345% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 181.769% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 294.899% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 2590.119% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -151200.504% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -23936.783% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 228.967% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 189.727% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | -36.151% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 2087.243% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 216.913% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -2089.41% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 162.283% |
| Immix Biopharma, Inc. | -17.5 Million USD | 962.095% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 147.663% |
| MEI Pharma, Inc. | -3.7 Million USD | 4174.251% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -1106.546% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 6.672% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | -443.126% |
| Fortress Biotech, Inc. | 7.66 Million USD | -1869.354% |
| Precigen, Inc. | -481 Thousand USD | 31482.744% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -972.019% |
| AlloVir, Inc. | -62.69 Million USD | 340.782% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 371.426% |
| Fate Therapeutics, Inc. | 61.66 Million USD | -144.788% |
| ImmuCell Corporation | 10.99 Million USD | -1273.46% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 197.927% |
| Onconetix, Inc. | 5.33 Million USD | -2731.338% |
| PureTech Health plc | -167.19 Million USD | 190.283% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 595.571% |
| Elevation Oncology, Inc. | -19.11 Million USD | 889.575% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 3174.985% |
| Seer, Inc. | -4.24 Million USD | 3660.165% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 727.994% |
| Innoviva, Inc. | 255.56 Million USD | 40.934% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 370.212% |
| ESSA Pharma Inc. | -33.62 Million USD | 548.971% |
| GlycoMimetics, Inc. | -40.98 Million USD | 468.313% |
| GT Biopharma, Inc. | -1.02 Million USD | 14884.623% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 322.697% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | -146.422% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 212.584% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 1189.427% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 622.828% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 200475.66% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 589.116% |
| Aptose Biosciences Inc. | -8.19 Million USD | 1942.021% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 4924.229% |
| Soligenix, Inc. | -4.95 Million USD | 3148.532% |
| Century Therapeutics, Inc. | 847 Thousand USD | -17721.842% |
| Kura Oncology, Inc. | -20.11 Million USD | 850.328% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 468.839% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 1897.464% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -8186.294% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 4821.645% |
| Autolus Therapeutics plc | -186.59 Million USD | 180.896% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 406.164% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 154.733% |
| Eterna Therapeutics Inc. | 34.26 Million USD | -340.501% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 8.163% |
| GRI Bio, Inc. | -1.79 Million USD | 8514.214% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 1780.399% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 553.892% |
| IGM Biosciences, Inc. | -72.6 Million USD | 307.904% |
| INmune Bio, Inc. | -25.41 Million USD | 694.038% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 397.975% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 1028.965% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 5332.405% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | -297.083% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 466.519% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -373.423% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 60.061% |
| Verastem, Inc. | -37.27 Million USD | 504.933% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 1763.739% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 391.063% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 1097.364% |
| Histogen Inc. | -7.48 Million USD | 2116.175% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 798.627% |
| Surrozen, Inc. | -32.66 Million USD | 562.133% |
| Organovo Holdings, Inc. | -1.5 Million USD | 10116.656% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 3691.089% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -696.146% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -5670.298% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -3532.122% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 1901.077% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 447.477% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 1135.552% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 147.65% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 21005.603% |
| Apollomics, Inc. | -27.39 Million USD | 651.017% |
| Amarin Corporation plc | -191.04 Million USD | 179.015% |
| Mesoblast Limited | 55.96 Million USD | -169.734% |
| Turnstone Biologics Corp. | -14.58 Million USD | 1135.045% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 696.833% |
| Synaptogenix, Inc. | -28.66 Million USD | 626.668% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 16227.244% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | -209.757% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 17609.909% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 2177.475% |
| Exelixis, Inc. | -73.05 Million USD | 306.641% |
| Better Therapeutics, Inc. | -860 Thousand USD | 17652.442% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 728.622% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 162.539% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -20407.808% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 2129.42% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -11937.56% |
| Gritstone bio, Inc. | 39.49 Million USD | -282.251% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 279.488% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 5834.915% |
| Avid Bioservices, Inc. | 169.72 Million USD | 11.063% |
| Insmed Incorporated | 721.62 Million USD | 79.082% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 1751.27% |
| MediWound Ltd. | -5.32 Million USD | 2936.359% |
| OmniAb, Inc. | 9.2 Million USD | -1540.237% |
| Alector, Inc. | -35.63 Million USD | 523.579% |
| Seres Therapeutics, Inc. | 85.97 Million USD | -75.584% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 3163.129% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -1040.199% |
| Zai Lab Limited | -775 Million USD | 119.478% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 55.675% |
| Aura Biosciences, Inc. | -21.52 Million USD | 801.282% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 283.015% |
| Immunic, Inc. | -45.34 Million USD | 432.931% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 178.126% |
| Veracyte, Inc. | -203.82 Million USD | 174.059% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 76.351% |
| FibroGen, Inc. | 56.76 Million USD | -165.913% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -1595.126% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 5439.463% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 7391.093% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 96.712% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 4618.138% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 190.954% |
| TG Therapeutics, Inc. | 17.86 Million USD | -745.096% |
| Galecto, Inc. | -21.21 Million USD | 811.496% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 734.648% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 90.382% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 716.831% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 1411.819% |
| XBiotech Inc. | -200.02 Million USD | 175.467% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 279.488% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -3233.723% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 528.072% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 295.487% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -2552.451% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 188.578% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 263.413% |
| Vaxxinity, Inc. | 10.13 Million USD | -1389.844% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 79.498% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 1501.907% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 328.866% |
| NexImmune, Inc. | -3.13 Million USD | 4917.109% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 4472.004% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 1098.918% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 657.015% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 1781.708% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 121272.787% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 472.057% |
| Ainos, Inc. | 4.07 Million USD | -3601.659% |
| Pluri Inc. | 22.82 Million USD | -561.225% |
| Prothena Corporation plc | -608.34 Million USD | 124.813% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 227.11% |
| Celularity Inc. | 65.19 Million USD | -131.555% |
| Rallybio Corporation | -24.1 Million USD | 726.301% |
| Cue Biopharma, Inc. | -33.81 Million USD | 546.35% |
| MeiraGTx Holdings plc | -40.3 Million USD | 474.55% |
| Omeros Corporation | 331.17 Million USD | 54.42% |
| Humacyte, Inc. | -22.48 Million USD | 771.311% |
| Immunocore Holdings plc | -358.59 Million USD | 142.095% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 714.246% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 588.499% |
| Blueprint Medicines Corporation | 702.83 Million USD | 78.523% |
| CalciMedica, Inc. | -5.53 Million USD | 2829.675% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 180.199% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 1577.883% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 477.029% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 553.947% |
| Pulmatrix, Inc. | -10.41 Million USD | 1549.083% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 2625.531% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 495.761% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 235.501% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 351.82% |
| Cytokinetics, Incorporated | 642.37 Million USD | 76.501% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 2692.324% |
| Nutriband Inc. | -251.65 Thousand USD | 60082.834% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 542.425% |
| Vor Biopharma Inc. | 4.3 Million USD | -3410.488% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 102.501% |
| Evogene Ltd. | -19.63 Million USD | 868.824% |
| ProKidney Corp. | -56.23 Million USD | 368.424% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 410.139% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 1734.166% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 88.932% |
| CorMedix Inc. | -43.05 Million USD | 450.621% |
| BioLineRx Ltd. | 7.33 Million USD | -1957.674% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 649.612% |
| Galectin Therapeutics Inc. | 46.14 Million USD | -227.109% |
| Atai Life Sciences N.V. | -28.55 Million USD | 628.577% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -6667.498% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 761.602% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -751.147% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 301.07% |
| MediciNova, Inc. | -50.78 Million USD | 397.244% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 291.55% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 671142.454% |
| GeoVax Labs, Inc. | -6.45 Million USD | 2439.387% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 175.543% |
| Biomea Fusion, Inc. | -166.57 Million USD | 190.623% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 184.342% |
| Mereo BioPharma Group plc | -51.46 Million USD | 393.285% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 259.157% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 151.386% |
| Absci Corporation | -72.59 Million USD | 307.927% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -3205.979% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 164.389% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 260.227% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 257.74% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 486.331% |
| Allakos Inc. | -24.97 Million USD | 704.408% |
| Imunon, Inc. | -4.21 Million USD | 3682.257% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 1123.952% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 211.485% |
| BioAtla, Inc. | -109.01 Million USD | 238.473% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -20407.808% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 16175.719% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -1161.499% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 811.932% |
| XOMA Corporation | -29 Million USD | 620.521% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 1011.54% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 1774.257% |
| aTyr Pharma, Inc. | -7.44 Million USD | 2126.46% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 221.113% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 172.515% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 284.584% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 262.728% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 17669.112% |
| Akari Therapeutics, Plc | -3.84 Million USD | 4025.904% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -9201.37% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 89.068% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 12804.869% |
| UroGen Pharma Ltd. | 4.39 Million USD | -3337.736% |
| Sutro Biopharma, Inc. | 113.48 Million USD | -33.019% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -209664.876% |
| Orgenesis Inc. | 21.78 Million USD | -592.944% |
| Entera Bio Ltd. | -10.62 Million USD | 1520.181% |
| GH Research PLC | -78.07 Million USD | 293.336% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 777.275% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 666.229% |
| Xencor, Inc. | 29.64 Million USD | -409.213% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 7763.219% |
| Replimune Group, Inc. | 1.41 Million USD | -10590.581% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 61735.798% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 219.407% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 12804.869% |
| Portage Biotech Inc. | -4.98 Million USD | 3130.536% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 671142.454% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 328.292% |
| OncoCyte Corporation | -6.56 Million USD | 2400.03% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -16720.683% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 3413.495% |
| Purple Biotech Ltd. | -14.13 Million USD | 1167.697% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 735.423% |
| scPharmaceuticals Inc. | -6.54 Million USD | 2406.356% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 1004.322% |
| HilleVax, Inc. | -165.48 Million USD | 191.217% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 6047.636% |
| Tharimmune, Inc. | -10.93 Million USD | 1480.395% |
| Genprex, Inc. | -6.73 Million USD | 2340.417% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 140.93% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 270.643% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 10874.518% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 4650.903% |
| OKYO Pharma Limited | -826.84 Thousand USD | 18356.197% |
| Savara Inc. | 153 Thousand USD | -98560.784% |
| Curis, Inc. | -23.88 Million USD | 731.938% |
| Daré Bioscience, Inc. | -5.15 Million USD | 3026.592% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 19552.148% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 2531.556% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -12638.481% |
| BeiGene, Ltd. | -2.25 Billion USD | 106.7% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -1123.415% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 124.819% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 181.337% |
| Erasca, Inc. | -37.21 Million USD | 505.608% |
| bluebird bio, Inc. | 108.57 Million USD | -39.034% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 11820.772% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 60.145% |
| DBV Technologies S.A. | -126.98 Million USD | 218.872% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 11820.772% |
| Moderna, Inc. | -2.9 Billion USD | 105.193% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 1558.182% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 1488.949% |
| Molecular Templates, Inc. | 707 Thousand USD | -21250.919% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 581.18% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 56.449% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 283.948% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 264.56% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 567.746% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 539.117% |
| MacroGenics, Inc. | -66.98 Million USD | 325.35% |
| RenovoRx, Inc. | -1.17 Million USD | 12968.798% |
| Adicet Bio, Inc. | -138.78 Million USD | 208.765% |
| Prime Medicine, Inc. | -27.94 Million USD | 640.249% |
| Aditxt, Inc. | 18.12 Million USD | -733.022% |
| Adagene Inc. | -87.62 Million USD | 272.265% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 3723.901% |
| Quantum-Si incorporated | -118.55 Million USD | 227.324% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | -319.25% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 2119.631% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 411.181% |
| SciSparc Ltd. | -2.06 Million USD | 7409.976% |
| Vericel Corporation | 1.27 Million USD | -11720.752% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 1358.796% |
| Minerva Neurosciences, Inc. | 41 Million USD | -268.135% |
| Generation Bio Co. | 31.44 Million USD | -380.002% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 186.079% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 588.151% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | -29.468% |
| Invivyd, Inc. | -198.47 Million USD | 176.055% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 267.222% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 6395.689% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 313.238% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 2311.736% |
| 2seventy bio, Inc. | 181.71 Million USD | 16.93% |
| ADMA Biologics, Inc. | 90.06 Million USD | -67.6% |
| Clene Inc. | 3.34 Million USD | -4419.491% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 1761.961% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 801.739% |
| GeoVax Labs, Inc. | -6.45 Million USD | 2439.387% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 143.865% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 680.588% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 15.037% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 3789.32% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -2917.813% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 2997.888% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 215.845% |
| Evaxion Biotech A/S | 5.28 Million USD | -2755.219% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 234.098% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 214.99% |
| Trevena, Inc. | 2.25 Million USD | -6585.164% |
| Surrozen, Inc. | -32.66 Million USD | 562.133% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 393.052% |
| Cingulate Inc. | 3.08 Million USD | -4796.741% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 5239.632% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -2000.334% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 1724.662% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 290.299% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 214.834% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 243.025% |
| Clearmind Medicine Inc. | -3.94 Million USD | 3928.681% |
| Kronos Bio, Inc. | -36.05 Million USD | 518.68% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -1504.326% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -10252.39% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 378.22% |
| Statera Biopharma, Inc. | 14.41 Million USD | -947.078% |
| ImmunityBio, Inc. | 618.22 Million USD | 75.583% |
| Korro Bio, Inc. | -132.94 Million USD | 213.546% |
| Kineta, Inc. | -4.54 Million USD | 3424.18% |
| BioVie Inc. | -17.73 Million USD | 951.275% |
| Codexis, Inc. | -43.27 Million USD | 448.85% |
| Celularity Inc. | 65.19 Million USD | -131.555% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 4863.364% |
| Celcuity Inc. | 6.78 Million USD | -2125.264% |
| Virax Biolabs Group Limited | -3.36 Million USD | 4585.988% |
| Cibus, Inc. | -8.07 Million USD | 1968.668% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 3669.425% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -3203.085% |
| IN8bio, Inc. | -16.38 Million USD | 1021.051% |
| Kodiak Sciences Inc. | -103.87 Million USD | 245.32% |
| Annexon, Inc. | -193.75 Million USD | 177.908% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -419208.333% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 962.626% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 4396.926% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 85.682% |
| Eyenovia, Inc. | 1.25 Million USD | -11892.592% |
| Puma Biotechnology, Inc. | 26.9 Million USD | -461.052% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 4754.672% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 554.029% |
| Arcellx, Inc. | -296.95 Million USD | 150.832% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 873.87% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 356.392% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 828.282% |
| Moolec Science SA | 117.61 Thousand USD | -128242.232% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 493.112% |
| Geron Corporation | 14.76 Million USD | -922.634% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 498.099% |
| Royalty Pharma plc | 5.65 Billion USD | 97.332% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 206.739% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 2259.706% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 2914.749% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 207.262% |
| Humacyte, Inc. | -22.48 Million USD | 771.311% |
| Structure Therapeutics Inc. | -124.33 Million USD | 221.403% |
| 89bio, Inc. | -289.05 Million USD | 152.223% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 698.015% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 8566.125% |
| Genelux Corporation | -6.89 Million USD | 2288.013% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 586.014% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | -80.566% |
| Notable Labs, Ltd. | -9.77 Million USD | 1644.098% |
| Liquidia Corporation | -80.17 Million USD | 288.275% |
| Mustang Bio, Inc. | -3.73 Million USD | 4140.444% |
| Immunovant, Inc. | -635.22 Million USD | 123.763% |
| Quantum-Si incorporated | -118.55 Million USD | 227.324% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 959.434% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 3743.519% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -1780.541% |
| Acasti Pharma Inc. | -23 Million USD | 756.166% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 4582.944% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 1028.965% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 209.591% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 4943.821% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 778.981% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 912.919% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 189.173% |
| PepGen Inc. | -60.67 Million USD | 348.807% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 756.994% |
| United Therapeutics Corporation | -507.7 Million USD | 129.732% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 889.245% |
| Solid Biosciences Inc. | -47.75 Million USD | 416.128% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 17609.909% |
| Immuneering Corporation | -54.94 Million USD | 374.742% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 3691.089% |
| Silo Pharma, Inc. | -3.52 Million USD | 4383.139% |
| Belite Bio, Inc | -87.27 Million USD | 272.968% |
| XOMA Corporation | -29 Million USD | 620.521% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 313.518% |
| Bionomics Limited | 227 Million USD | 33.505% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 229.815% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 6059.376% |
| uniQure N.V. | -102.95 Million USD | 246.624% |
| Cassava Sciences, Inc. | -121.13 Million USD | 224.613% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 3723.901% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | -268.614% |
| Forte Biosciences, Inc. | -11.96 Million USD | 1362.027% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 4978.515% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -142306.604% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 4754.672% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -1595.126% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 2135.477% |
| Altimmune, Inc. | -134.48 Million USD | 212.242% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 23.787% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 6059.376% |
| Compugen Ltd. | -12.9 Million USD | 1269.8% |
| Peak Bio, Inc. | 10.34 Million USD | -1359.852% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 53439.576% |
| Benitec Biopharma Inc. | -50.58 Million USD | 398.428% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 244.675% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -668.394% |
| Zura Bio Limited | -99.8 Million USD | 251.244% |
| PolyPid Ltd. | 6.17 Million USD | -2346.532% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | -103.658% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -668.394% |
| Instil Bio, Inc. | 75.35 Million USD | -100.312% |
| argenx SE | -2.02 Billion USD | 107.44% |
| Immunome, Inc. | -97.02 Million USD | 255.573% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 771.042% |
| Verona Pharma plc | -220.44 Million USD | 168.476% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 310.405% |
| Shattuck Labs, Inc. | -121.42 Million USD | 224.317% |
| CervoMed Inc. | -7.79 Million USD | 2037.046% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 181.376% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 3551.887% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 214.583% |
| Moolec Science SA | 117.61 Thousand USD | -128242.232% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 6697.575% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -849.474% |
| AnaptysBio, Inc. | -18.15 Million USD | 931.64% |
| Design Therapeutics, Inc. | -18.15 Million USD | 931.686% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 314.477% |
| NeurAxis, Inc. | 145.7 Thousand USD | -103503.981% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -1243.937% |
| Lumos Pharma, Inc. | -28.49 Million USD | 629.783% |
| Achilles Therapeutics plc | -126.92 Million USD | 218.93% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 310.405% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 23120.298% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 826.64% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -10252.39% |
| Nutriband Inc. | -251.65 Thousand USD | 60082.834% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 1246.086% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 2128.911% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 55.628% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | -535.985% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 133.734% |
| Palisade Bio, Inc. | -12.06 Million USD | 1351.355% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 207.583% |
| Beam Therapeutics Inc. | -262.72 Million USD | 157.457% |
| Neurogene Inc. | -131.95 Million USD | 214.396% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | -591.928% |
| AEON Biopharma, Inc. | -4.88 Million USD | 3193.258% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 140.02% |
| Sesen Bio, Inc. | -112.55 Million USD | 234.115% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 251.163% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 6529.485% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 486.796% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 281.253% |
| Athira Pharma, Inc. | -88.99 Million USD | 269.61% |
| Vaccinex, Inc. | -1.28 Million USD | 11819.798% |
| HCW Biologics Inc. | 2.85 Million USD | -5184.148% |
| XOMA Corporation | -29 Million USD | 620.521% |
| Nektar Therapeutics | 210.24 Million USD | 28.201% |
| Arvinas, Inc. | -313.8 Million USD | 148.104% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -9201.37% |
| Merus N.V. | -192.88 Million USD | 178.26% |
| Omega Therapeutics, Inc. | 59.98 Million USD | -151.648% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 2275.713% |
| Rezolute, Inc. | -68.16 Million USD | 321.44% |
| Clene Inc. | 3.34 Million USD | -4419.491% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 1244.696% |
| BeyondSpring Inc. | -13.75 Million USD | 1197.426% |
| Synlogic, Inc. | -6.68 Million USD | 2358.055% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -13211.376% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 1885.346% |
| Peak Bio, Inc. | 10.34 Million USD | -1359.852% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 283.149% |
| Krystal Biotech, Inc. | -350.23 Million USD | 143.1% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | -21.612% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 189.322% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 4881.252% |
| MannKind Corporation | 143.89 Million USD | -4.901% |
| Ikena Oncology, Inc. | -109.15 Million USD | 238.289% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 2093.805% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 556.045% |
| Gossamer Bio, Inc. | 180.35 Million USD | 16.303% |
| CohBar, Inc. | -5.93 Million USD | 2645.234% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 607.432% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -3205.979% |
| Legend Biotech Corporation | -949.39 Million USD | 115.9% |
| Mural Oncology plc | -255.84 Million USD | 159.001% |
| Biora Therapeutics, Inc. | 32.21 Million USD | -368.574% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 3304.468% |
| Disc Medicine, Inc. | -358.28 Million USD | 142.132% |
| Champions Oncology, Inc. | 4.81 Million USD | -3036.97% |
| REGENXBIO Inc. | 54.76 Million USD | -175.619% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 56235.021% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 199.952% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 1774.999% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 287.091% |
| Vaxart, Inc. | -8.24 Million USD | 1931.707% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 400.819% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 218.704% |
| Cellectis S.A. | -43.85 Million USD | 444.205% |
| Longeveron Inc. | -2.9 Million USD | 5290.887% |
| Repare Therapeutics Inc. | -107.85 Million USD | 239.953% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 84.412% |
| Inozyme Pharma, Inc. | 12 Million USD | -1157.506% |
| Revolution Medicines, Inc. | -608.2 Million USD | 124.819% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 12372.439% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 156.938% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 200.586% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 1064.728% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 20498.784% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 101.578% |
| Denali Therapeutics Inc. | -74.86 Million USD | 301.631% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 1358.796% |
| Veru Inc. | 4.77 Million USD | -3057.991% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 1442.264% |
| Cingulate Inc. | 3.08 Million USD | -4796.741% |
| Passage Bio, Inc. | 4.58 Million USD | -3192.279% |
| Context Therapeutics Inc. | -14.44 Million USD | 1144.656% |
| Exicure, Inc. | 5.84 Million USD | -2480.8% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 165.524% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 481.478% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -862.023% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 356.628% |
| Nuvalent, Inc. | -335.38 Million USD | 145.008% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -8603.652% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 302.668% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 1797.987% |
| OmniAb, Inc. | 9.2 Million USD | -1540.237% |
| Anew Medical, Inc. | 1.43 Million USD | -10437.849% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -821.458% |
| Lipocine Inc. | -4.75 Million USD | 3274.847% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 237.443% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -891.077% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 397.975% |
| G1 Therapeutics, Inc. | 24.89 Million USD | -506.424% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 2345.96% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 329.315% |
| Ocugen, Inc. | -32.52 Million USD | 564.165% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 276.396% |
| Q32 Bio Inc. | -37.94 Million USD | 497.784% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 24136.783% |
| Alumis Inc. Common Stock | -13.52 Million USD | 1215.759% |
| Equillium, Inc. | -22.39 Million USD | 774.129% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 690.39% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 562.66% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 60988.208% |
| Galera Therapeutics, Inc. | 134.04 Million USD | -12.615% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -4620.169% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -45859.853% |
| Dominari Holdings Inc. | 195 Thousand USD | -77310.769% |
| Edesa Biotech, Inc. | -5.26 Million USD | 2966.026% |
| vTv Therapeutics Inc. | -8.91 Million USD | 1792.845% |
| Bio-Techne Corporation | 267.74 Million USD | 43.622% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 1031.279% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 227.823% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 1896.394% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 1293.194% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 161.583% |
| Nkarta, Inc. | 57.29 Million USD | -163.444% |
| BioCardia, Inc. | 212 Thousand USD | -71103.302% |
| Iterum Therapeutics plc | 13.43 Million USD | -1023.314% |